Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DNTH NASDAQ:INDV NASDAQ:LEGN NASDAQ:OLMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNTHDianthus Therapeutics$86.16+1.0%$84.21$16.64▼$96.50$4.71B1.18902,809 shs612,371 shsINDVIndivior$36.76-2.8%$32.84$11.04▼$41.00$4.48B0.92.36 million shs1.82 million shsLEGNLegend Biotech$27.55-3.7%$21.10$16.24▼$45.30$5.10B0.292.38 million shs1.80 million shsOLMAOlema Pharmaceuticals$13.59-1.7%$15.60$3.89▼$36.26$1.19B2.051.44 million shs1.22 million shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNTHDianthus Therapeutics-0.47%-0.15%-10.08%+80.04%+351.53%INDVIndivior-1.36%-4.47%+14.74%+9.40%+242.97%LEGNLegend Biotech-0.24%+0.11%+53.02%+62.68%+2.88%OLMAOlema Pharmaceuticals+1.77%-8.66%-15.21%-38.82%+207.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNTHDianthus Therapeutics$86.16+1.0%$84.21$16.64▼$96.50$4.71B1.18902,809 shs612,371 shsINDVIndivior$36.76-2.8%$32.84$11.04▼$41.00$4.48B0.92.36 million shs1.82 million shsLEGNLegend Biotech$27.55-3.7%$21.10$16.24▼$45.30$5.10B0.292.38 million shs1.80 million shsOLMAOlema Pharmaceuticals$13.59-1.7%$15.60$3.89▼$36.26$1.19B2.051.44 million shs1.22 million shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNTHDianthus Therapeutics-0.47%-0.15%-10.08%+80.04%+351.53%INDVIndivior-1.36%-4.47%+14.74%+9.40%+242.97%LEGNLegend Biotech-0.24%+0.11%+53.02%+62.68%+2.88%OLMAOlema Pharmaceuticals+1.77%-8.66%-15.21%-38.82%+207.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNTHDianthus Therapeutics 3.00Buy$117.8236.74% UpsideINDVIndivior 3.00Buy$39.337.00% UpsideLEGNLegend Biotech 2.67Moderate Buy$59.00114.16% UpsideOLMAOlema Pharmaceuticals 2.71Moderate Buy$44.10224.50% UpsideCurrent Analyst Ratings BreakdownLatest OLMA, DNTH, INDV, and LEGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026LEGNLegend Biotech Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$62.00 ➝ $64.005/13/2026LEGNLegend Biotech TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$29.005/13/2026LEGNLegend Biotech Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$49.00 ➝ $48.005/13/2026OLMAOlema Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$38.00 ➝ $35.005/6/2026INDVIndivior Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/6/2026LEGNLegend Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/6/2026DNTHDianthus Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$103.00 ➝ $105.004/21/2026OLMAOlema Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026LEGNLegend Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.004/20/2026DNTHDianthus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026LEGNLegend Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNTHDianthus Therapeutics$2.04M2,309.00N/AN/A$21.98 per share3.92INDVIndivior$1.24B3.62$2.61 per share14.10($1.18) per share-31.15LEGNLegend Biotech$1.14B4.47N/AN/A$5.23 per share5.27OLMAOlema PharmaceuticalsN/AN/AN/AN/A$5.50 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNTHDianthus Therapeutics-$162.34M-$4.13N/AN/AN/A-12,998.50%-27.30%-25.91%N/AINDVIndivior$210M$1.9518.859.99N/A19.44%-219.26%29.40%7/30/2026 (Estimated)LEGNLegend Biotech-$296.80M-$0.68N/A16.40N/A-21.98%-24.92%-14.87%N/AOLMAOlema Pharmaceuticals-$162.45M-$2.02N/AN/AN/AN/A-46.00%-41.22%N/ALatest OLMA, DNTH, INDV, and LEGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026LEGNLegend Biotech-$0.02-$0.03-$0.01-$0.30$306.51 million$305.10 million5/12/2026Q1 2026OLMAOlema Pharmaceuticals-$0.52-$0.52N/A-$0.52N/AN/A5/5/2026Q1 2026DNTHDianthus Therapeutics-$1.0719-$0.85+$0.2219-$0.85$0.40 million$0.46 million4/30/2026Q1 2026INDVIndivior$0.64$0.96+$0.32$3.45$272.84 million$317.00 million3/31/2026Q1 2026INDVIndiviorN/A$0.96N/A$3.45N/A$317.00 million3/16/2026Q4 2025OLMAOlema Pharmaceuticals-$0.51-$0.50+$0.01-$0.50N/AN/A3/11/2026Q4 2025LEGNLegend Biotech-$0.17$0.01+$0.18-$0.16$310.21 million$306.30 million3/9/2026Q4 2025DNTHDianthus Therapeutics-$0.97-$1.43-$0.46-$1.43$0.40 million$0.57 million2/27/2026Q4 2025INDVIndivior$0.65$0.82+$0.17$3.95$305.62 million$358.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDNTHDianthus TherapeuticsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNTHDianthus TherapeuticsN/A29.2529.25INDVIndiviorN/A0.860.66LEGNLegend BiotechN/A2.131.91OLMAOlema Pharmaceuticals0.0110.889.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNTHDianthus Therapeutics47.53%INDVIndivior60.33%LEGNLegend Biotech70.89%OLMAOlema Pharmaceuticals91.78%Insider OwnershipCompanyInsider OwnershipDNTHDianthus Therapeutics3.02%INDVIndivior0.74%LEGNLegend Biotech0.02%OLMAOlema Pharmaceuticals12.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNTHDianthus Therapeutics8054.67 million53.02 millionOptionableINDVIndivior1,051121.92 million121.02 millionNot OptionableLEGNLegend Biotech2,965184.96 million184.92 millionOptionableOLMAOlema Pharmaceuticals7087.35 million76.38 millionOptionableOLMA, DNTH, INDV, and LEGN HeadlinesRecent News About These CompaniesOlema Pharmaceuticals (NASDAQ:OLMA) Price Target Cut to $35.00 by Analysts at GuggenheimMay 14 at 4:16 AM | americanbankingnews.comOlema Oncology Reports First Quarter 2026 Financial and Operating ResultsMay 12 at 5:16 PM | markets.businessinsider.comOlema Pharmaceuticals inc Ordinary Shares OLMAMay 10, 2026 | morningstar.comMAssessing Olema Pharmaceuticals (OLMA) Valuation After Adding Dr. Prakash Raman To The BoardMay 10, 2026 | finance.yahoo.comOlema Pharmaceuticals (OLMA) to Release Quarterly Earnings on TuesdayMay 10, 2026 | americanbankingnews.comPier Capital LLC Decreases Position in Olema Pharmaceuticals, Inc. $OLMAMay 8, 2026 | marketbeat.comOlema Pharmaceuticals (OLMA) Expected to Announce Quarterly Earnings on TuesdayMay 5, 2026 | marketbeat.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 4, 2026 | globenewswire.comJennison Associates LLC Takes Position in Olema Pharmaceuticals, Inc. $OLMAMay 2, 2026 | marketbeat.comPictet Asset Management Holding SA Trims Stock Holdings in Olema Pharmaceuticals, Inc. $OLMAMay 2, 2026 | marketbeat.comOlema Pharmaceuticals Adds Veteran Director to Support GrowthApril 29, 2026 | tipranks.comOlema Oncology Appoints Prakash Raman, Ph.D., to Board of DirectorsApril 29, 2026 | globenewswire.comWall Street Zen Upgrades Olema Pharmaceuticals (NASDAQ:OLMA) to "Sell"April 27, 2026 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsApril 22, 2026 | marketbeat.comOlema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual MeetingApril 21, 2026 | globenewswire.comOlema Pharmaceuticals (NASDAQ:OLMA) Downgraded to "Strong Sell" Rating by Wall Street ZenApril 19, 2026 | marketbeat.comOlema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual MeetingApril 18, 2026 | theglobeandmail.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2026 | globenewswire.comJim Cramer on Olema Pharmaceuticals: “Too Risky for Me”March 24, 2026 | msn.comOlema Shelf Registration Raises Questions On Dilution And Funding FlexibilityMarch 23, 2026 | finance.yahoo.comOlema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?March 22, 2026 | fool.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOLMA, DNTH, INDV, and LEGN Company DescriptionsDianthus Therapeutics NASDAQ:DNTH$86.16 +0.82 (+0.96%) Closing price 04:00 PM EasternExtended Trading$86.06 -0.10 (-0.12%) As of 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Indivior NASDAQ:INDV$36.76 -1.07 (-2.83%) Closing price 04:00 PM EasternExtended Trading$36.35 -0.41 (-1.10%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Legend Biotech NASDAQ:LEGN$27.55 -1.05 (-3.67%) Closing price 04:00 PM EasternExtended Trading$27.13 -0.42 (-1.52%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Olema Pharmaceuticals NASDAQ:OLMA$13.59 -0.23 (-1.66%) Closing price 04:00 PM EasternExtended Trading$13.61 +0.02 (+0.15%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Viking Sails to All-Time Highs—Fundamentals Signal More to Come YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs McDonald's Is the Cheapest It’s Been in Years—Does That Make It a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
